Immatics N.V. — Regulatory Filings 2021

Mar 17, 2021

6-K 1 dp147933_6k.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 6-K

Field: Rule-Page

Field: /Rule-Page

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

March 17, 2021

Commission File Number: 001-39363

Field: Rule-Page

Field: /Rule-Page

IMMATICS N.V.

Field: Rule-Page

Field: /Rule-Page

Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of Principal Executive Office)

Field: Rule-Page

Field: /Rule-Page

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Field: Rule-Page

Field: /Rule-Page Field: Page; Sequence: 1

Field: /Page

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 17, 2021, Immatics N.V. (the “Company”) issued a press release providing a data update on dose escalation from its ongoing ACTengine ® cell therapy programs. A copy the press release is attached hereto as Exhibit 99.1.

EXHIBITS

Exhibit Number	Description
99.1	Press release dated March 17, 2021.

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| /s/
Harpreet Singh |
| --- |
| Harpreet Singh |
| Chief Executive Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page